Diaphragm Hibernation and Its Driving Factors in Mechanically Ventilated ICU Patients

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRadboud University Medical Center

About this trial

Rationale:

Patients with invasive mechanical ventilation (IMV) frequently develop diaphragm dysfunction and experience difficult weaning. Recent ex vivo work suggests that a subset of mechanically ventilated ICU patients may exhibit diaphragm hibernation, an energy conserving myosin state that reduces force generation and may lead to a reversible increase in diaphragm strength over time. However, it is unknown whether diaphragm hibernation can be demonstrated in vivo during IMV and which clinical and biological factors are associated with this phenotype.

Objective:

Primary objective is to determine the driving factors (biomarkers) of diaphragm hibernation during IMV. Secondary objectives are to determine the proportion of ventilated critically ill patients who exhibit diaphragm hibernation during IMV, to investigate inflammatory and metabolic factors and other clinical exposures associated with diaphragm hibernation, and to explore associations between diaphragm hibernation and weaning related and survival outcomes.

Study design:

Prospective, observational, longitudinal cohort study.

Study population:

Adult ICU patients receiving IMV, expected to remain mechanically ventilated for at least 72 hours.

Intervention (if applicable):

Not applicable. This is an observational study. Study specific procedures consist of repeated phrenic nerve magnetic stimulation and additional blood sampling.

Main study parameters/endpoints:

The primary study parameter is the proportion of participants exhibiting diaphragm hibernation during IMV. Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0-1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death. Ptr,stim will be assessed repeatedly on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Participant burden is limited and mainly consists of repeated phrenic nerve magnetic stimulation during a ventilator delivered end expiratory occlusion and additional blood sampling of 9.5 mL per time point, up to a total of 47.5 mL across the study period. Magnetic stimulation is non-invasive and expected discomfort is transient. Rare transient physiological changes may occur and measurements are performed under continuous ICU monitoring and will be postponed or omitted if considered unsafe or interfering with clinical care. Direct benefit for participants is limited, but the study may provide clinically relevant knowledge on diaphragm hibernation and its driving factors. The research questions are specific to diaphragm physiology during IMV in critically ill patients, therefore the study is group related and cannot be performed in a different population.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years.

Receiving invasive mechanical ventilation at screening.

Expected to remain mechanically ventilated for ≥ 72 hours from enrolment.

The first study assessment can be performed within 36 hours after initiation of invasive mechanical ventilation.

Disqualifiers

Pre-existing neuromuscular disease affecting the diaphragm (e.g. motor neuron disease, myasthenia gravis, advanced muscular dystrophy, high cervical spinal cord injury) or use of neuromuscular blocker.

Known phrenic nerve palsy or prior diaphragmatic paralysis.

Long-term home mechanical ventilation (invasive or non-invasive) prior to ICU admission.

Post-operative patients after planned diaphragm or phrenic nerve surgery.

Trial population

The study population consists of newly admitted adult ICU patients receiving invasive mechanical ventilation, in whom the first study assessment can be performed within 36 hours after initiation of IMV and who are expected to require IMV for at least 3 days.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

112 Participants
are grouped into 1 trial group
Group A: Patients with expected > 3 days of invasive mechanical ventilation

Trial outcomes

Primary outcomes

1

Blood C reactive protein level

C reactive protein will be assessed by blood sample.

Time frame
C reactive protein will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
2

Blood procalcitonin level

Procalcitonin will be assessed by blood sample.

Time frame
Procalcitonin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
3

Blood metabolic biomarkers level

Metabolic biomarkers will be assessed by blood sample using OLINK Target 96 panel.

Time frame
Metabolic biomarkers will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
4

Blood TNF-α level

TNF-α will be assessed by blood sample.

Time frame
TNF-α will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.

Secondary outcomes

1

Proportion of participants exhibiting diaphragm hibernation during invasive mechanical ventilation

Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0 to 1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death.

Time frame
Ptr,stim will be assessed repeatedly on Day 0 to 1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
2

Number of days from intubation to successful extubation

Data about number of days from intubation to successful extubation will be retrieved from electronic medical records.

Time frame
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
3

Number of days from first SBT to successful extubation

Data about number of days from first SBT to successful extubation will be retrieved from electronic medical records.

Time frame
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
4

Incidence of weaning failure

Weaning failure is defined as SBT failure or reintubation within 48 hours. Data will be retrieved from electronic medical records.

Time frame
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: